HAVRIX is an inactivated vaccine used to prevent hepatitis A, a serious liver disease caused by the hepatitis A virus (HAV). This vaccine works by stimulating the body's immune system to produce antibodies against the hepatitis A virus, providing immunity and preventing infection. HAVRIX is administered through an injection, typically into the muscle of the upper arm, and is recommended for individuals at high risk of infection or for those traveling to areas where hepatitis A is common. The vaccination schedule involves one initial dose followed by a booster dose, usually 6 to 12 months later, for long-term protection. HAVRIX is considered safe and effective for both adults and children over the age of one year, offering protection against hepatitis A, which can range from a mild illness lasting a few weeks to a severe illness lasting several months.